CG MedTech Co.,Ltd. (KOSDAQ:056090)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,165.00
+26.00 (2.28%)
At close: Sep 4, 2026

CG MedTech Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
51,19947,23534,62334,96941,16938,055
Other Revenue
-0--0-0-0-
51,19947,23534,62334,96941,16938,055
Revenue Growth
19.80%36.43%-0.99%-15.06%8.18%37.01%
Cost of Revenue
30,15026,37218,83417,13922,51822,571
Gross Profit
21,04920,86315,78917,82918,65115,484
Selling, General & Admin
13,76711,68212,43013,95212,63810,525
Research & Development
3,7593,7593,3574,4624,4714,893
Amortization of Goodwill & Intangibles
311.4311.486.4897.52106.96137.85
Other Operating Expenses
221.49221.49127.64117.83143.14126.68
Operating Expenses
19,17317,06016,88515,62628,82816,299
Operating Income
1,8763,802-1,0962,204-10,177-815.21
Interest Expense
-176.29-176.29-185.71-535.88-6,317-1,294
Interest & Investment Income
474.32474.32571.87374.56592.34102.16
Earnings From Equity Investments
--15.75---
Currency Exchange Gain (Loss)
-50.89-50.89691.8148.54382.6490.54
Other Non Operating Income (Expenses)
2,044107.47141.31-262.14-3,896-160.49
EBT Excluding Unusual Items
4,1674,157138.851,929-19,416-1,677
Gain (Loss) on Sale of Investments
-1,421-1,421-258.52-340.46672.25191.93
Gain (Loss) on Sale of Assets
172.92172.92132.53261.96165.7723.41
Asset Writedown
-173.18-173.18--463.9--3,944
Other Unusual Items
----156.54-
Pretax Income
2,7462,73612.861,387-18,421-5,406
Income Tax Expense
-3,791-3,772137.7980.88386.87-190.67
Earnings From Continuing Operations
6,5366,508-124.941,306-18,808-5,215
Minority Interest in Earnings
17.35-184.63323.44268.83244.37
Net Income
6,5546,50859.691,629-18,540-4,970
Net Income to Common
6,5546,50859.691,629-18,540-4,970
Net Income Growth
156.93%10801.84%-96.34%---
Shares Outstanding (Basic)
10210360796745
Shares Outstanding (Diluted)
10210360796745
Shares Change
13.85%72.99%-24.33%18.55%49.47%16.01%
EPS (Basic)
64.5563.021.0020.65-278.64-111.66
EPS (Diluted)
64.5563.021.0020.65-279.00-112.00
EPS Growth
125.67%6202.12%-95.16%---

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-22,777-8,866736.7-4,068-6,184375.08
Free Cash Flow Per Share
-224.36-85.8612.34-51.58-92.958.43
Gross Margin
41.11%44.17%45.60%50.99%45.30%40.69%
Operating Margin
3.66%8.05%-3.17%6.30%-24.72%-2.14%
Profit Margin
12.80%13.78%0.17%4.66%-45.03%-13.06%
Free Cash Flow Margin
-44.49%-18.77%2.13%-11.63%-15.02%0.99%
EBITDA
4,8636,066596.094,057-7,9771,347
EBITDA Margin
9.50%12.84%1.72%11.60%-19.38%3.54%
D&A For EBITDA
2,9872,2641,6921,8532,2012,162
EBIT
1,8763,802-1,0962,204-10,177-815.21
EBIT Margin
3.66%8.05%-3.17%6.30%-24.72%-2.14%
Effective Tax Rate
--1071.82%5.83%--
Advertising Expenses
-59.8285.15351.37311.16176.3